Abstract: Single domain antibodies (sdAbs) from camels or sharks comprise only the variable heavy chain domain. Human sdAbs comprise the variable domain of the heavy chain (VH) or light chain (VL) and can be selected from human antibodies. SdAbs are stable, nonaggregating molecules in vitro and in vivo compared to complete antibodies and scFv fragments. They are excellent novel inhibitors of cytosolic/nuclear proteins because they are correctly folded inside the cytosol in contrast to scFv fragments. SdAbs are unique because of their excellent specificity and possibility to target posttranslational modifications such as phosphorylation sites, conformers or interaction regions of proteins that cannot be targeted with genetic knockout techniques and are impossible to knockdown with RNAi. The number of inhibiting cytosolic/nuclear sdAbs is increasing and usage of synthetic single pot single domain antibody libraries will boost the generation of these fascinating molecules without the need of immunization. The most frequently selected antigenic epitopes belong to viral and oncogenic proteins, followed by toxins, proteins of the nervous system as well as plant-and drosophila proteins. It is now possible to select functional sdAbs against virtually every cytosolic/ nuclear protein and desired epitope. The development of new endosomal escape protein domains and cell-penetrating peptides for efficient transfection broaden the application of inhibiting sdAbs. Last but not least, the generation of relatively new cell-specific nanoparticles such as polymersomes and polyplexes carrying cytosolic/nuclear sdAb-DNA or -protein will pave the way to apply cytosolic/ nuclear sdAbs for inhibition of viral infection and cancer in the clinic.
Introduction
New insights into the function of proteins can be obtained with nucleotide-based knockout and knockdown methods at the DNA or mRNA level respectively. Knockdown and knockout methods are essential to analyze the function of proteins.
Knockdown of proteins complement these methods and is essential if post-translational modifications, conformations and interaction regions of proteins have to be studied. Regarding knockdown at the mRNA level this cannot be achieved with siRNA technology. Today, protein inhibitors are dominant negative mutants, small molecule inhibitors including peptides, allosteric modulators, short single-stranded DNA or RNA oligonucleotides (aptamers, intramers), neutralizing antibodies and intrabodies and nonimmunoglobulin binder scaffolds such as cysteine-knot proteins, adnectins, anticalins, affibodies, and DARPins. 1, 2 Another class of promising knockdown molecules recently gaining importance are intracellular antibodies (intrabodies), i.e. antibodies that are expressed within the target cell that contains the corresponding antigen. Intrabodies are recombinant antibody fragments and the main advantages are their high specificity such that post-translational modifications, interaction regions, conformers, splice variants and isoforms can be targeted without off target effects. Long lasting functional inhibition of intracellular proteins can be achieved, which is not possible with classical neutralizing antibodies. Intrabodies can be specifically transported to the cytosol, nucleus or ER to bind their antigens at specific loci only (Fig. 1) .
The development of cytosolic/nuclear intrabodies was hampered by the fact that intrabodies in the scFv and Fab format cannot form disulfide bridges within the reducing environment of the cytosol and are therefore unstable. 3, 4 Specific strategies were developed such as the yeast two-hybrid system 5 to express functional cytosolic/nuclear scFv intrabodies and usage of these methods led to some remarkable functional cytosolic/ nuclear scFv intrabodies. 6 A breakthrough in antibody engineering was the discovery of stable expressed cytosolic/nuclear sdAbs derived from camel or shark antibodies comprising only the variable domain of the heavy chain. The variable domain of camelid heavy chain antibodies is called VHH, the variable domain of the new antigen receptor (IgNAR) from sharks vNAR. Camelid VHHs recognizing their antigens are called nanobodies. Both single domain antibodies derived from camels or sharks constitute intact functional antigen-binding sites, the single domain VHH domain with 3 complementarity determining CDR regions 7 and the vNAR domain with CDR1, CDR3
and HV2 and HV4. [8] [9] [10] Camelid and shark single domain antibodies possess good solubility, high thermal stability and refolding capability. 7, 10, 11 In addition, stable human VH and VL domains can be constructed from human antibodies after framework mutations and randomization of CDRs. [12] [13] [14] [15] [16] [17] [18] Camelid nanobodies can be stably expressed inside the Figure 1 . ScFvs and sdAbs targeted to subcellular compartments. Intrabodies can be targeted to the ER, mainly as scFv fragment, where they are retained by the KDEL sequence (red line). Binding of the specific antigen will lead to retention of the antigen-ER-intrabody complex inside the ER (not shown). Alternatively, scFvs or sdAbs can be targeted to the nucleus or cytosol via a nucleus leader peptide (green line) or without leader sequence, respectively. Complementarity-determing regions are shown by lines. sdAbs from shark have only CDR1 and CDR3.
cytoplasm even if the disulfide bridge is not formed. 2, 6 Folded nanobodies can find their antigen and are then stabilized by binding to the antigen.
As an analytical tool camelid antibodies have been used to illuminate in vivo trafficking of target molecules, to detect conformational states and posttranslational modification of proteins. In addition, they have been employed as chaperons for crystallization in cases where unstable proteins are sensitive to degradation, unfolding or aggregation. [19] [20] [21] [22] [23] In general nanobodies are selected from na€ ıve, immune, synthetic camelid VHH single domain antibody repertoires [24] [25] [26] [27] whereas shark sdAbs and human VH and VL sdAbs are mainly selected from synthetic antibody libraries. 12-1828-34 Antibody fragments are displayed on filamentous phages or yeast. Selected sdAbs can then be converted to cytosolic/nuclear intrabodies with a single cloning step (Figs. 2 and 3 ). In particular, universal synthetic nanobody libraries are very valuable because no immunization with the target antigen is needed. Low affinity binders can be affinity-maturated by introducing CDR mutations, randomization of mutational hotspots or by error prone PCR. [35] [36] [37] The number of available inhibiting nanobodies against different cytosolic/nuclear proteins is increasing. So far most cytosolic/nuclear single domain intrabodies have been derived from camels, followed by some single domains VH and VL of human origin (Table I) .
The targets comprise intracellular enzymes including kinases: 53, 54, 58, 59, 62, [76] [77] [78] 81 oncogenic proteins [56] [57] [58] [59] [60] [62] [63] [64] [65] 68, 69, 81 Figure 2. Construction and application of cytosolic/nuclear camelid nanobodies. Until now, most cytosolic camelid nanobodies have been constructed after immunization of camels. The VHH domains will be amplified from the cDNA isolated from the peripheral blood lymphocytes of immunized camels. Then a phage display repertoire is generated to display the VHH repertoire on the surface. Biopanning with the antigen will deliver specific recombinant nanobody phages from which the genes can be cloned into an appropriate targeting vector for expression in the cytosol or nucleus. The function of the intrabody can be tested in cell culture or applied in a xenograft tumor mouse model. Alternatively, a transgenic mouse expressing the nanobody can be generated. (P, promoter; R, resistant gene; Nb, nanobody; NLS, nucleus leader sequence). toxins 53255 proteins of the nervous system [70] [71] [72] [73] and virus proteins [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] proteins from plants and drosophila [77] [78] [79] [80] Most cytosolic/nuclear sdAbs have been evaluated in living cells but in vivo application of single domain intrabodies in mice is well documented, too. 57, 60, 81 In the future, generation of transgenic mice expressing cytosolic/nuclear sdAb is possible and very useful if a corresponding genetic knockout is lethal.
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ER intrabodies versus cytosolic/nuclear intrabodies ER-intrabody knockdown function is based on retention of molecules passing the secretory pathway via the KDEL sequence fused to the C-terminal end of the intrabody. 6, [83] [84] [85] In the past ER-intrabodies have been the most promising molecules because they are correctly folded in the ER environment. 86 Contrary to ER intrabodies which have only to bind to the antigen inside the ER, cytosolic/nuclear intrabodies have to inactivate their targets by binding to the antigen and inducing a conformational change or interfering with the binding of the target protein to its specific binding partner. Intrabodies targeted to the ER (ER-intrabodies) are mostly expressed as scFv fragment, cytosolic/nuclear intrabodies as scFv or recently as much more stable single domain antibody. 6, 87, 88 Due to the high stability of sdAbs in the cytosol/nucleus compared to scFv fragments and efficient reliable selection techniques based on phage and yeast display, the knockdown of cytosolic/nuclear proteins by sdAbs is very promising.
Cytosolic/nuclear intrabodies
To select stable correctly folded scFv fragments, specific in vivo selection in eukaryotes such as yeast or in prokaryotes such as E.coli has to be performed. 6 Possible options are also expression of scFv-protein fusions and CDR grafting or introduction of Figure 3 . Construction and application of cytosolic/nuclear human VH and VL domains. Synthetic human VH/VL libraries are constructed from a stable human VH or VL germline framework or from a VH/VL scaffold of an existing antibody. After randomization of the CDRs (mainly CDR3) and possible introduction of framework mutations, human VH and VL are displayed on phages. Specific sdAbs are selected by biopanning and the sdAb-coding region is subsequently cloned into a targeting vector for expression inside the cytosol or nucleus. In vivo application follows. (P, promoter; R, resistant gene; NLS, nucleus leader sequence; sdAb, single domain antibody). PERV-A/B Virus production is blocked upon expression of intrabody.
Dekker et al. Drosophila Decapentaplegic-(Dpp) GFP Into the framework of an anti-ß-lactamase VHH were transplanted the CDRs of an anti-GFP VHH An anti-eGFP VHH -CD8 transmembrane domain -cytoplasmic mCherry fluorescent tag-fusion protein (morphotrap) was expressed in a transgenic mouse expressing DPP-GFP to trap GFP-Dpp on the cell surface.
The wing disc development was analyzed.
When Dpp is immobilized on the cell surface, wing disc patterning is lost and lateral cells still devide at normal rates.
Harmansa et al. 80 synthetic CDRs in stable frameworks. 6 The most frequently used method to select functional scFv's is the Antibody Capture Technology (IACT) based on the yeast 2-hybrid system. 5 The next paragraph summarizes the targets against which scFv fragments have been selected by IACT and describes some new scFv's inhibiting the degradation of p53 and restoring the activity of mutated p53, respectively.
ScFv format
Many different scFv's have been isolated by IACT, for example against Tau, amyloid-ß peptide, asynuclein, proNGF, gephyrin, Syk, EGFR, BCR-ABL, caspase 3, aggrecanase-2 and NSP5 from rotavirus. 6 Recently, a scFv fragment against the E6 oncoprotein of HPV selected by IACT was targeted to the nucleus where it inhibits the ability of HPV16 E6 (16E6) to mediate p53 degradation and causes cell death of HPV16-positive cells. 89 Additionally, the nucleus-targeted intrabody inhibited tumor activity of HPV16-positive tumor cells in two pre-clinical mouse models. Interestingly, two bispecific scFv fragments have been constructed that (1) comprises a scFv that targets the nucleus and a scFv fragment that restored the function of mutated p53 and (2) comprises the intracellular nuclear transport scFv fragment and a scFv fragment that binds Mdm2 and prevents destruction of p53 by Mdm2. 90 All three scFv fragments were constructed from corresponding hybridoma clones.
Single domain format
In contrast to the time-consuming strategies for selection of functional cytosolic/nuclear scFv's, nanobodies can be directly selected from immune, na€ ıve or synthetic libraries displayed on phage or yeast which significantly shortens the isolation of binders. Single domain antibodies are composed of only one V region (variable domain of the heavy or light chain) and in numerous examples it was shown that sdAbs can be stably expressed inside the cytoplasm or nucleus (Table I ). In the next paragraph, current methods for construction and selection of camelid, shark and human sdAbs including new developments will be summarized.
Generation of cytosolic/nuclear single domain intrabodies
Single domains antibodies can be generated from camelid heavy-chain IgGs (VHHs), from cartilaginous fish IgNARs (V s NAR ) or from conventional human IgGs (VH and VL). The antibody repertoires can be derived after immunization of camels or sharks, build up from na€ ıve natural antibody sequences or synthetically constructed based on stable scaffolds. 10, 24, [56] [57] [58] 61, 63, 81 However, the process of immunization of sharks is demanding in comparison to immunization of mammals. Therefore, shark nanobodies have mostly been selected from synthetic repertoires. Human single domain VH and VL domains were selected from synthetic human VH or VL antibody repertoires.
Strategies to Construct Camelid VHH Repertoires

Construction of immune camelid VHH libraries
Camelid VHHs repertoires for the selection of single domain antibodies are mostly generated after immunization of camels. PCR amplification of VHH can be performed with primers binding to the N-terminus and CH2 region of camel heavy chain IgG cDNA, followed by nested PCR amplifying the VHH coding region. The product is cloned into a phagemid vector and a phage antibody repertoire established 91 ( Fig. 2) . Na€ ıve and synthetic single domains libraries have the advantage that no immunization of animals is needed. A disadvantage is that the selected sdAbs are not affinity maturated. Nevertheless, if these libraries contain a high number of clones with high diversity, sdAbs against all possible targets and epitops should be identifyable. Selected sdAbs can then easily be converted into cytosolic/nuclear antibody fragments by one cloning step (Fig. 3) . In the next paragraphs, the principles of the generation of na€ ıve and synthetic libraries together with some new developments are shown.
Examples of cytosolic/nuclear nanobodies from immune camelid VHH libraries
Construction of na€ ıve camelid VHH libraries
Na€ ıve llama VHH libraries are single pot or universal libraries generated from blood samples from several animals for the selection of a large number of different specificities. 92 Na€ ıve libraries with different sizes have been constructed ranging from 10 7 to 5 310 9 clones. 25, 93 Recently, ribosome display with nanobodies has been performed with an expression cassette that can easily be used for in vitro synthesis of ribosome-VHH complexes in different expression systems. 94 
Examples of cytosolic/nuclear naive VHHs
Some interesting na€ ıve cytosolic/nuclear nanobodies have been generated particularly against nonstructural membrane protein NSB4 of HCV, 45 Bax,
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NS3 helicase of HCV, 46 RNA dependent RNA polymerase NS5B, 47 nuclear poly(A)-binding protein 1 (PABPN1) 75 and Caspase-3.
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Construction of synthetic VHH libraries
Synthetic camelid VHH libraries have been constructed based on natural VHH frameworks. Antigen binding diversity has been introduced by randomization of the CDRs, mainly CDR3. 95 Interestingly, a semi-synthetic library has been constructed from 3 unimmunized llamas. In this case, the CDRs and frameworks were diversified by errorprone PCR and then these sequences were spliced together through the common framework overlaps by PCR.
96,97
Examples of synthetic cytosolic/nuclear nanobodies A specific nanobody that leads to cytoplasmic accumulation of heterogenous nuclear ribonucleoprotein K (hnRPN-K) has been selected. 63 Furthermore, a nanobody that significantly inhibits the enzyme activity of potato starch branching enzyme has been generated. 77 Recently, a very stable variant of an anti-GFP nanobody was constructed by transplantation of the CDRs from an anti-GFP VHH to a stable framework of an anti-ß lactamase VHH. 98 This antibody was part of the morphotrap that was used to analyze the function of Drosophila Decapentaplegic (Dpp) on wing disc development.
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Non camelid sdAb libraries 3) . Recently a synthetic library was constructed comprising the Ig1 domain of human neural cell adhesion molecule 1 (NCAM) in which randomized CDR1 and CDR3 from a shark clone were transplanted. 100 Chimeric antibodies were selected that block the signaling activity of chemokine receptor CXCR4.
Construction of synthetic human VH/VL libraries
Examples of synthetic human VH/VL cytosolic/ nuclear sdAbs. Anti-myc human VH single domain antibodies have been selected from a synthetic human VH library based on a VH consensus framework of an anti-RAS scFv. Stepwise randomization of CDR3, CDR2 and CDR1 followed by yeast two hybrid system selection led to specific anti-cmyc clones. 56, 61 Similarly, an anti-RAS human VH and anti-LIM domain only 2 (LMO2) VH domain was selected. 57, 81 The anti-RAS VH inhibited RASdependent tumorigenesis in a mouse tumor model and the anti-LM02 antibody fragment inhibits T-cell neoplasia in a nude mouse. An anti-epithelial kinase (Etk) human VL was selected from a synthetic library based on a human OE domain framework with randomized CDR3s. 58 Furthermore, camelization of human VHs can be performed by introduction of point mutations in the VH framework of an human antibody, mainly framework 2 to render the overall structure more hydrophilic. 88 Such camelized human VH frameworks have been used to generate CDR3 randomized single domain antibody repertoires displayed on phages for selection of new binders with improved solubility and refolding efficiency. 101, 102 Interestingly a rabbit-derived anti-HIV Vif VH single-domain intrabody was active in its camelized format. 41 
Construction of synthetic IgNAR variable domain (vNAR) libraries
In general, vNAR libraries have been selected from semi-synthetic libraries based on naturally occurring vNAR sequences and randomized CDR 3 loops.
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A shark anti-hen egg-white lysozyme IgNAR VH clone was used as the scaffold for the generation of a semi-synthetic library with randomized CDR 3 loops. 33 Interestingly, a neutralizing VNAR singledomain antibody against BAFF that blocked the binding of BAFF to all three of its receptors was selected recently. In this case, the shark antibody repertoire was based on Type 2 nurse shark VNAR frameworks with a number of framework mutations and partial randomization of CDR3. 34 At present, no shark cytosolic/nuclear sdAb have been reported in the literature.
Selection of cytosolic/nuclear sdAbs
For selection of antigen-specific sdAbs, the sdAb repertoires are displayed on phages or on the cell surface of yeast cells. Then, by incubation of the recombinant phage antibody repertoire with immobilized antigen (biopanning), specific binders will be selected and cloned into a cytosolic or nuclear targeting vector (Figs. 2 and 3) . The cytosolic or nuclear intrabodies will be evaluated in target cells, in xenograft tumor mouse models or transgenic sdAb mice.
Recently, a promising screening method to identify functional sdAbs has been developed. 103 Alpacas were immunized with a mixture of inactivated influenza A virus (IAV) and vesicular stomatitis virus (VSV). Generated VHH cDNAs were subsequently directly cloned into a retroviral vector to produce lentivirus particles. Then, A549 cells were infected with recombinant viruses and after 48 h treated with a lethal dosis of IAV and VSV. Surviving colonies were further characterized and the sequences of the VHHs were determined. After this screen, 19 VHHs that specifically block infection of cells with IAV or VSV were isolated. This screening approach should be applicable to identify inhibitors of any pathogen or biological pathway. Most sdAbs have been selected by phage display without additional usage of the bacterial-, yeast-or mammalian-two hybrid system. This approach is usually reliable and can be used for selection of cytosolic/nuclear scFv fragments as well as sdAbs because cytosolic/nuclear selection will favor wellfolded scFv fragments or sdAbs rather than the high affinity ones. However, it is still unclear if the affinity of antibodies is the only prerequisite for efficient intrabody engineering. Usage of bacterial-, yeast-or mammalian-two hybrid systems enables direct in vivo selection of functional cytosolic/nuclear intrabodies without the need of purified antigen. [104] [105] [106] Another two-hybrid assay that allows studying the interaction of two proteins in living cells directly has been developed. 107 Here, a fluorescently labeled prey protein and the corresponding bait protein fused to fluorescently labeled lacI are coexpressed in mammalian cells that contain chromosomally integrated lac operator. Interaction of both molecules results in co-localization of two different fluorescent signals at the lac operator, which can be observed as a spot within the nucleus. The next paragraph provides a list of the selection and description of all known cytosolic/nuclear sdAbs derived from camels and human antibodies. Cytosolic sdAbs are descripted which have been successfully applied in xenograft tumor models and in addition a nanobody-GFP fusion protein is highlighted which is universally applicable for monitoring protein knockout in living cells.
Examples of cytosolic/nuclear single domain antibodies
Cytosolic/nuclear nanobodies that interfere with the function of approximately 40 cytosolic/nuclear targets have been generated successfully (Table I: reports of cytosolic/nuclear sdAb mediated knockdown). Compared to this number of cytosolic/nuclear targets ER-intrabodies against approximately 35 transitory proteins have been reported. Most sdAbtargets belong to viral or oncogenic proteins, followed by toxins and proteins of the nervous system.
Cytosolic intrabodies have also successfully been expressed in plants and in Drosophila. Single domain intrabodies partially protected potato plants against potato virus Y. 78 A universal method has been developed to monitor protein knockout in living cells. 79 To achieve this anti-GFP VHHs were fused to an F-box domain of Drosophila Slmb for degradation of targets fused to GFP via the ubiquitin depletion pathway. The technique was applied for the degradation of a transcription factor and a protein involved in morphogenesis of transgenic Drosophila monogaster flies expressing GFP-target protein and anti-GFP VHH. In addition an anti-eGFP -CD8 transmembrane domain -cytoplasmic mCherryfusion protein (morphotrap) was developed to study wing disc development in transgenic flies expressing eGFP-morphogenetic protein Decapentaplegic (Dpp) and the morphotrap. The morphotrap immobilized eGFP-Dpp on the cell surface, leading to inhibition of wing disc patterning. 80 Even gene silencing using sequence-selective and nucleic-acid hydrolyzing nanobodies is now possible. 108 Most sdAbs have been tested in cell culture and only few have been investigated in mice as an animal model. SdAbs against LIM domain only 2 (LMO2), F-Actin capping protein CapG and RAS were tested in appropriate xenograft tumor mouse models by transplanting tumor cells expressing the corresponding intrabody in nude mice or NOD-SCID mice. 57, 60, 81 In addition an anti-HIV-1 Nef intrabody was able to rescue Nef-mediated thymic CD4 1 T-cell maturation defect and peripheral CD4 1 T-cell activation phenotypes in CD4
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/HIV NEF transgenic mice. 42 Interestingly, fusion of a loop of a SH3 domain to one selected nanobody improved some inhibiting HIV-1 Nef functions. 43 Furthermore a cysteine-free human VL has been selected 71 with better activity as the original antibody fragment. Interestingly changing the cysteine residues to valine and alanine led to lower affinity as the original antibody domain with the cysteins. An improved cysteine-free variant could be selected after random mutagenesis using error-prone PCR. Several nanobodies against viral proteins, toxins, oncogenic proteins and proteins of the nervous system have therapeutic potential (table: reports of cytosolic/nuclear sdAb mediated knockdown). In the next paragraph new developments in protein delivery of scFv fragments/sdAbs and model proteins into the cytosol/nucleus of target cells will be shown.
Protein transfection with cytosolic/nuclear sdAbs
Alternatively to viral transfection or plasmid transfection, intrabodies can be delivered as proteins into the cytosol (profection). Delivery of intrabodies in the scFv or nanobody format into the cytosol of a target cell has the advantage that the intrabodies retain their disulfide bridges for correct folding. Further, this method might be a safe alternative to viral gene transfer for clinical approaches.
The delivery of antibodies to the cytosol using different profection reagents has been studied in detail and was compared to electroporation, which was found to be the most effective reliable technique. 109 Alternatively, fusion of cell penetrating peptides or targeting proteins (ligands or antibodies) together with translocation domains or usage of cell penetrating peptides fused to endosome escape domains has been investigated. 109, 110 Fusion of peptides and proteins to reach the cytoplasm is often not very efficient because of inefficient endosomal escape. 110 However, a cell penetrating anti-DNA antibody localizes to the nucleus through a nucleoside salvage pathway and is used as a delivery vehicle and combined with specific targeting scFvs. 90 Some highlights referring to cell-penetrating peptides should be mentioned. Highly efficient delivery was achieved using a cell-penetrating peptideadaptor system built of TAT-calmodulin fusion and a fusion consisting of calmodulin binding site and cargo. 111 TAT-calmodulin non-covalently binds, delivers and releases cargo into the cytoplasm. Another system uses cell-penetrating peptides binding to heparan sulfate glycosaminoglycan fused to a protein transduction domain. Cell types that are generally difficult to transduce, such as mouse embryonic stem cells (mESCs), human ESCs and human induced pluripotent stem cells (hiPSCs), have been efficiently transfected. 112 Furthermore, camelid nanobodies against HCV proteins have been fused to cell penetrating penetrin and were successfully applied in HVC infected cells. [45] [46] [47] 113 It was shown that the osteoblast transcription factor Runx2 can be targeted to the nucleus of mesenchymal cells by the peptide dentin phosphophoryn, bypassing the lysosomal degradation pathway. 114 Recently, an efficient serum-stable and low-toxic molecular transporter comprising one rigid planar core and four flexible arms with one guanidinium group on each arm was constructed to efficiently deliver small cargoes and large active proteins into cytosol. 115 A very interesting approach combined the TAT cell penetrating peptide to an endosomal escape sequence and GFPß11 peptide. Endosomal escape can be measured by binding of GFPß11 to non-fluorescent GFP ß1-10, inducing chemical formation of the GFP fluorescent chromophore. The assay enables screening of the next generation of endosomal escape domains. 116 In addition, highly efficient cyclic cell-penetrating peptides have been designed. These cyclic peptides are characterized by efficient release from the endosome. 117 Last but not least, the solvent exposed residues of the framework region of nanobodies have been mutated to positively charged arginines or lysines (cationic resurfacing), leading to cell penetration. 118 This approach has the potential to build a general applicable scaffold to transport nanobodies into the cell. A very promising additional approach is the usage of the type VI secretion pathway of pathogenic bacteria to transport sdAbs into human cells. 119 The injection of the sdAbs does not require bacterial invasion or the transfer of genetic material. The approach to deliver drugs or toxins specifically to tumors mediated by nanoparticles decorated with nanobodies has been demonstrated in many in vitro examples and is now beginning to be tested in vivo. 88 
Conclusion
Single domain antibodies from camels, shark and humans are very useful to efficiently and specifically knock down cytosolic and nuclear proteins in vivo.
The option to specifically target interaction regions, conformers, splice variants, isoforms and even posttranslational modifications such as phosphorylation sites 21, 22, 34, 58, [125] [126] [127] The availability of synthetic universal, single-pot camelid, shark and human single domain antibody libraries displayed on phages or yeast cells enables selection of a huge number of different single domain intrabodies theoretically directed against any antigen and desired epitope. 12218, 28231, 33, 34, 95, 96, 132 By using antibody affinity maturation strategies, binders with high affinity can be isolated from these nonaffinitymaturated universal libraries by introducing CDR mutations, randomization of mutational hotspots or error prone PCR. 35237 Usage of a recently published method based on selection of specific inhibitory dAbs by recombinant lentiviruses to omit phage display selection will be attractive in the future.
Strategies to apply cytosolic/nuclear single domain intrabodies in the clinic may become possible with cell penetrating peptides, [45] [46] [47] 113 new optimized endosomal escape domains, 116 sdAb expression plasmids or recombinant sdAbs embedded into nanoparticles such as polymersomes and polyplexes. 88 For cell-and tissue-specific transductional targeting, nanoparticles can be decorated with anti-receptor sdAbs. Application of mRNA coding for cytosolic/nuclear single domain intrabodies might also be possible in the future. 133, 134 In summary, cytosolic/nuclear sdAbs of camelid, shark and human origin can be applied to clarify the function of uncharacterized proteins such as virus proteins and host cell factors, oncogenic proteins and cofactors, proteins of the nervous system, intracellular enzymes involved in signaling, transcription factors and proteins involved in differentiation and development.
